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We aimed to investigate whether wearing-off symptoms at the end of the natalizumab dosing
interval were associated with clinical and demographic patient characteristics or natalizumab
receptor occupancy (RO) on leukocytes.
Methods
In this cross-sectional study of 40 patients with relapsing-remitting MS (RRMS) receiving
natalizumab at the Department of Neurology, Haukeland University Hospital, we recorded
clinical and demographic data including age, body mass index (BMI), working status, smoking
habits, disease characteristics, treatment duration, vitamin D levels, and wearing-off symptoms.
We quantified neurofilament light chain in serum and measured natalizumab RO in leukocyte
subtypes by high-parameter mass cytometry. Associations with wearing-off symptoms were
analyzed.
Results
Eight (20.0%) patients who reported regular occurrence of wearing-off symptoms, 9 (22.5%)
who sometimes had wearing-off symptoms, and 23 (57.5%) who did not have wearing-off
symptoms were evaluated. Patients who regularly had wearing-off symptoms had lower nata-
lizumab RO than patients who reported having such symptoms sometimes or never. The
former group also had higher BMI and higher frequency of sick leave. High BMI was associated
with low RO. No other demographic or disease characteristics were associated with the
phenomenon.
Conclusions
Low RO may explain the wearing-off phenomenon observed in some patients with RRMS
treated with natalizumab, and high BMI may be the underlying cause.
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Natalizumab (Tysabri®, Biogen, Cambridge, MA) is a thera-
peutic monoclonal antibody used to treat patients with
relapsing-remitting MS (RRMS). It prevents leukocyte mi-
gration across the blood-brain barrier into the CNS by
binding to the α4 subunit of the α4β1 integrin (α4 integrin) on
leukocyte surfaces.1 Natalizumab is administered IV at
a standard dose of 300 mg every 4 weeks.
Although highly efficacious in preventing disease activity,
many patients report the so-called wearing-off symptoms at
the end of the 4-week dosing interval. Although wearing-off
symptoms are often reported, only a few previous studies have
described the phenomenon, and little is known about the
underlying causes of these symptoms.2–5
Natalizumab receptor occupancy (RO) is defined as the level
of natalizumab bound to α4 integrin on leukocytes and is
a potential biomarker to monitor and individualize natalizu-
mab therapy.6 RO has traditionally been measured with flow
cytometry. Mass cytometry is a novel technology for high-
parameter single-cell analysis. For mass cytometry, detection
antibodies are conjugated to metals instead of fluorophores,
allowing analysis of over 40 parameters simultaneously on
single cells.7 This permits measurement of RO in conjunction
with more markers and in more cell types of interest than is
currently possible by flow cytometry. We aimed to investigate
whether clinical and demographic patient characteristics or
natalizumab RO were associated with the wearing-off phe-
nomenon by using high-parameter mass cytometry to mea-
sure natalizumab RO in patients with RRMS treated with
natalizumab who do and do not report wearing-off symptoms
at the end of dosing intervals.
Methods
Patients
We invited all patients older than 18 years with a diagnosis of
RRMS who had received a minimum of 6 natalizumab infu-
sions at the Department of Neurology, Haukeland University
Hospital (n = 45) to participate in this cross-sectional study; 40
agreed to participate. At inclusion, we obtained baseline de-
mographic and clinical patient characteristics from the patients’
medical journal including age, sex, disease duration (years since
first MS symptoms), natalizumab treatment duration (years
since first natalizumab infusion), numbers of new MRI lesions
and clinical relapses in the last year before inclusion, serum
vitamin D level, Symbol Digit Modalities Test score,8 and
Expanded Disability Status Scale score.9 Each patient filled in
questionnaires on fatigue (Fatigue Severity Scale),10 and on
working status, smoking habits, weight, height, and whether
they had wearing-off symptoms (never, sometimes, and regu-
larly), and, if applicable, type of symptoms.
Standard protocol approvals, registrations,
and patient consents
The study was approved by the Regional Committee for
Medical Research Ethics, Western Norway (REK 2016/579),
and written informed consent was obtained from all partici-
pating patients.
Blood samples
At inclusion, we collected blood before and after natalizumab
infusion. For mass cytometry analysis, whole blood was col-
lected in heparinized Vacutainer tubes (Greiner Bio-One
GmbH, Kremsmünster, Austria), incubated with Proteomic
Stabilizer (Smart Tube, Inc, San Carlos, CA) for 10 minutes,
and stored at −80°C. Whole blood was then thawed, and red
blood cell lysis was performed with Thaw-lyse buffer I (Smart
Tube, Inc) to obtain peripheral blood leukocytes (PBLs). For
neurofilament measurement, whole blood was collected in
Vacutainer tubes with no additives (BD, Plymouth, United
Kingdom), incubated at room temperature for 60 minutes,
and centrifuged at room temperature at 3,200g for 13 minutes
before the serum was retrieved and stored at −80°C.
Neurofilament measurement
Serum samples were thawed, and the concentration of neu-
rofilament light chain (NF-L) was measured with a single-
molecule array (Simoa) assay (Quanterix, Billerica, MA)
according to the manufacturer’s protocol.
Mass cytometry RO assay
PBLs were stained with a 36-parameter mass cytometry an-
tibody panel (table e-1, links.lww.com/NXI/A190). Bound
natalizumab was detected with an anti-IgG4 antibody (con-
jugated to 169Tm). Total α4 integrin was detected with an
anti-CD49d antibody (conjugated to 141Pr) specific for a dif-
ferent epitope than natalizumab. The 36 metal-conjugated
antibodies were purchased preconjugated (Fluidigm, South
San Francisco, CA), or antibodies were purchased (BioL-
egend, San Diego, CA, R&D Systems, Minneapolis, MN, and
Abcam, Cambridge, Great Britain) and conjugated in-house
to metals with the Maxpar Antibody Labeling Kit (Fluidigm).
Briefly, we thawed, barcoded (Cell-ID 20-Plex Pd Barcoding
Kit, Fluidigm), and pooled PBL samples in batches of 20
randomly distributed samples, keeping paired samples from
the same patients in the same batch. A control PBL sample
from 1 healthy donor was included in each batch. Pooled
PBLs were first incubated in Maxpar cell stain buffer with 100
U/mL heparin (LEO Pharma A/S) for 20 minutes at room
temperature11 and then incubated with the antibody cocktail
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for 30 minutes at room temperature. Stained PBLs were
washed, fixed in fresh 2% paraformaldehyde (Thermo Sci-
entific, Waltham, MA) in Maxpar PBS for 10 minutes at room
temperature, and then incubated in 125 nM Cell-IDTM
Intercalator-Ir in Maxpar Fix and Perm Buffer (Fluidigm) at
4°C overnight. We performed all centrifugation steps at room
temperature at 800g.
Before mass cytometry analysis, PBLs were resuspended in
0.1× EQ Four Element Calibration Beads (Fluidigm) in
Maxpar cell acquisition solution (Fluidigm) and filtered
(Corning Falcon Test Tube with Cell Strainer Snap Cap,
Fisher Scientific, Hampton, NN). We used antibody binding
QSC beads (Bangs Laboratories, Inc., catalog number 815A,
Fishers, IN) to standardize signal intensities from anti-IgG4
(conjugated to 169Tm) and anti-CD49d (conjugated to 141Pr)
as previously described in detail.12We analyzed PBL andQSC
beads with the same standard settings on a Helios® mass
cytometer (Fluidigm) after tuning (CyTOF Tuning Solution,
Fluidigm) and calibration (EQ Four Element Calibration
Beads, Fluidigm) according to the manufacture’s guidelines.
Healthy control PBLs served as a negative control for anti-
IgG4 in the absence of natalizumab, and patient PBLs in-
cubated in vitro with natalizumab to an expected RO of 100%








Patients with RRMS, n (%) 40 (100) 23 (57.5) 9 (22.5) 8 (20.0)







Sex, female, n (%) 25 (62.5) 15 (65.2) 3 (33.3) 7 (87.5) 0.069 0.063
Height, cm 171 (166–179) 169 (165–173) 180 (177–182) 171 (167–173) 0.078 0.047














Current smoker, n (%) 7 (17.5) 4 (17.4) 2 (22.2) 1 (12.5) 0.873 0.860
Sick leave, n (%) 9 (22.5) 2 (8.7) 3 (33.3) 4 (50.0) 0.04 0.013
Disease duration, y 13.0 (8.0–17.0) 13.0 (8.0–17.5) 13.0
(8.0–17.0)
12.5 (8.8–16.0) 0.949 0.798
Treatment duration, y 4.0 (3.0–7.3) 4.0 (3.0–8.5) 5.0 (3.0–6.0) 4.5 (2.0–8.0) 0.999 0.904














EDSS score 2.0 (1.0–3.5) 2.0 (1.0–3.5) 2.0 (1.5–2.5) 2.0 (1.5–3.1) 0.880 0.682
FSS score 4.8 (3.3–5.7) 4.6 (3.3–5.4) 4.3 (3.0–6.1) 5.3 (4.8–5.8) 0.223 0.186







New lesions detected by MRI in last
year
0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0) — —
Relapse activity in last year 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0) — —









Serum NF-L, pg/mL 6.1 (4.5–8.9) 8.0 (5.8–9.6) 5.1 (4.3–5.9) 4.6 (4.1–5.3) 0.011 0.390
Abbreviations: BMI = body mass index; EDSS = Expanded Disability Status Scale; FSS = Fatigue Severity Scale; SDMT = Symbol Digit Modalities Test; NF-L =
neurofilament light chain. RRMS = relapsing-remitting MS.
Numbers are median (interquartile range) unless otherwise stated.
a Unadjusted p values are calculated using a Kruskal-Wallis test.
b Age-adjusted p values are calculated with a likelihood ratio test between a linear model with only age and a linear model with age and the relevant baseline
variable as predictors.
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served as positive controls. Further quality control experi-
ments were performed as previously described in detail.12
Data processing, analysis, and statistics
After acquisition of QSC beads, we normalized (Fluidigm
normalizer) and exported FCS files to Cytobank software
(Cytobank, Inc., Beckman Coulter, Brea, CA) and created QSC
bead standard curves (QuickCal template, Bangs Laboratories).
After acquisition of PBL samples, we normalized (Fluidigm
normalizer), debarcoded (Fluidigm Debarcoder), and exported
the FSC files to Cytobank software for gating and downstream
analysis (figure e-1, links.lww.com/NXI/A190). We performed
clean-up gating to obtain single PBLs, and the data were arcsinh
transformed with a scale argument of 5.13 We then performed 2
independent analyses for RO calculation in single PBLs: one
was a manual analysis, and one used an unsupervised approach.
In the manual approach, we first identified the following 11
leukocyte subtypes of interest by manual gating: CD8+ central
memory (TCM), effector memory (TEM), effector memory
RA (TEMRA) T cells; CD4
+ TEM, TCM, and TEMRA cells;
CD34+ cells; memory B cells; natural killer (NK) cells;
monocytes; and conventional dendritic cells (cDCs).We then
plotted the signal intensities (dual count 90th percentiles) of
anti-IgG4 and anti-CD49d in each of these cell types with the
QSC bead standard curves to obtain bead standardized values
and calculated %RO by the following formula:
%RO = 100 ×
QSC bead standardized anti − IgG4 ð169TmÞ
QSC bead standardized anti −CD49d ð141PrÞ
We compared ROs in the leukocyte subtypes in different
patient groups using a Kruskal-Wallis test.
In the unsupervised approach, we used R (version 3.4.3) to add
an extra variable into the FSC files: the ratio between signal
intensities of anti-IgG4 and anti-CD49d in each cell. This
resulted in an RO estimate for each cell. For visualization of
high-dimensional single-cell data, we performed automated di-
mensionality reduction with stochastic neighborhood embed-
ding (viSNE, Cytobank).14 We analyzed the new RO variable
with the cluster identification, characterization, and regression
tool CITRUS (Cytobank), an algorithm that automatically
identifies statistically significant differences between patient
groups.15We applied the correlativemodel SignificanceAnalysis
of Microarrays with a false discovery rate (adjusted for multiple
hypothesis testing) of 1%. CITRUS was run with 10 repetitions.
The relationship between baseline demographic variables and
wearing-offwas compared using a Kruskal-Wallis test. Statistical
differences with p < 0.05 were considered significant using
a 2-sided comparison. To test the age-corrected relationship
between baseline variables and wearing-off, we used a likelihood
ratio test between a linear model with only age and a linear
model with age and the relevant baseline variable as predictors.
We conducted a linear regression of the association between
RO and body mass index (BMI) and used a t test to assess
whether the slope was significantly different from zero. We used
R version 3.4.316 for statistical analysis and correlation plots.
Data availability
FCS files from anonymized patient PBL samples can be
accessed in the Flow Repository (ID: FR-FCM-Z2A9).
Results
Patient characteristics
Of the 45 patients who were eligible for inclusion, 40 (89%)
consented to participate in the study. Of 5 (11%) non-
consenting patients, 1 refused participation, and 4 had infusion
time points outside of the opening hours of the routine labo-
ratory where blood samples were collected. Eight (20.0%) of
the 40 participating patients reported having wearing-off
symptoms regularly at the end of every dosing interval, 9
(22.5%) sometimes did, and 23 (57.5%) reported never having
wearing-off symptoms (table 1). Themost frequent wearing-off
symptom was fatigue (table 2). Patients who regularly had
wearing-off symptoms had significantly higher BMI and higher
frequency of sick leave than patients who never or only
sometimes experienced such symptoms (table 1). After age
adjustment, weight was also significantly increased in patients
with wearing-off symptoms regularly, whereas height was in-
creased in patients with symptoms only sometimes. None of
the other demographic or clinical patient characteristics were
significantly different between the groups, and none of the
included patients had clinical relapses or new lesions onMRI in
the year before inclusion in the study. Age-adjusted median
serum NF-L levels were similar between groups. There was no
association between NF-L and BMI (data not shown).
Receptor occupancy
Manual gating of PBLs correlated well with the automated
mapping with viSNE (figure 1A). We observed a broad range of
natalizumab RO values. The median RO values in all leukocyte
subtypes before infusion and in 10 of 11 leukocyte subtypes
after infusion (figure 1B) were lower in patients who regularly
experienced wearing-off symptoms than in patients who never
or only sometimes experienced such symptoms. The differences
were statistically significant in CD8+ TEM, CD4
+ TEM, and






Walking difficulty 11% 25%
Spasms 11% 13%
Pain 0% 13%
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Figure 1Natalizumab receptor occupancy (RO) in patients reportingwearing-off symptoms never, sometimes, or regularly
(A) Manually gated PBLs visualized on a viSNEmap. ROwas analyzed in 11 cell subtypes: CD8+ central memory (TCM), effectormemory (TEM), effectormemory
RA (TEMRA) cells; CD4
+ TEM, TCM, and TEMRA cells; CD34
+ cells; memory B cells; natural killer (NK) cells; monocytes; and conventional dendritic cells (cDCs).
Neutrophils were not included in RO analysis. (B) Spider plot ofmedian RO values in 11 cell subtypes in patients before and after natalizumab infusion. (C) RO
values in 11 cell subtypes before and after natalizumab infusion. p values (Kruskal-Wallis test) comparing ROs in different wearing-off groups. (D) Left: median
RO values in cell clusters significantly different betweenwearing-off groups (SAM analysis in CITRUS). Right: significant cell clusters are visualized on the viSNE
map. PBL = peripheral blood leukocyte; SAM = Significance Analysis of Microarrays.
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+ TCM cells, NK cells, monocytes, and cDCs after
infusion (figure 1C). Furthermore, in CD8+ and CD4+ T cells
not stratified into subtypes, RO was significantly lower in both
CD8+ and CD4+ T cells before infusion and in CD8+ T cells
after infusion in patients who regularly had wearing-off symp-
toms (figure e-2, links.lww.com/NXI/A190). Unsupervised
analysis of median ROs with CITRUS also showed lower me-
dian natalizumab ROs in patients with regular wearing-off
symptoms (figure 1D). Neither of the 2 analysis approaches
showed significant differences between patients reporting
wearing-off symptoms sometimes and never.
High BMI was associated with significantly lower RO in CD8+
TEM cells and cDCs before infusion and in CD8
+ TEMRA cells,
CD34+ cells, and monocytes after infusion (figure 2).
Discussion
Natalizumab prevents disease activity in RRMS and has
positive effects on subjective symptoms such as mood, fatigue,
and cognitive function.17,18 However, subjective wearing-off
symptoms at the end of the 4-week interval are frequently
reported by patients. In this study, wearing-off symptoms
were reported by 42.5% of the patients (20.0% regularly and
22.5% only sometimes). We found lower natalizumab ROs in
patients who regularly experienced wearing-off symptoms
compared with patients who reported such symptoms never
or only sometimes. The result was replicated in 2 separate
data analysis pipelines. Furthermore, patients who reported
regularly experiencing wearing-off symptoms had higher
median body weight and BMI and higher sick leave frequency
than those who rarely or never experienced such symptoms.
Median height was increased in patients with symptoms only
sometimes. Other clinical and demographic factors were
similar between the patient groups. High BMI was associated
with low RO in several leukocyte subtypes.
The main limitation of our study is the small patient cohort. As
a consequence of this limited statistical power, we were only
able to detect large effects and acknowledge that there may be
associations of smaller effect size that went unnoticed.Wearing-
off symptoms were less frequent in our study than the preva-
lence of 54%–63% reported in other studies, but as previously
reported, the most frequent wearing-off symptom was
fatigue.2–5 In contrast to our results, a recent study found no
association between the wearing-off effect and natalizumab RO
or patient characteristics.5 The previously reported study used
flow cytometry to measure RO in CD8+ TEM cells and CD8
+
effector T cells. By using high-parameter mass cytometry, we
were able to measure RO in 11 cell subtypes simultaneously.
We found that patients who regularly experienced wearing-off
symptoms had higher BMI than those who did not, and we also
observed an association between high BMI and low RO. Body
weight was higher in our cohort than in the previous study5
(median 75.0 vsmean 72.9 kg) andwas evenmore pronounced
in the groupwith wearing-off symptoms regularly (median 81.5
vs mean 74.6 kg). van Kempen et al.5 reported nonsignificant
trends similar to our significant results. Our wearing-off pop-
ulation had higher body weight than theirs, which may explain
why we observed statistically significant differences despite our
small cohort size. The association between high BMI and low
RO suggests that high BMI, by decreasing natalizumab RO,
may be the underlying cause of the wearing-off phenomenon.
Others have previously reported such an association between
low natalizumab RO and high body weight or BMI, and some
have suggested that the dose of natalizumab should be adjusted
for body weight.6,19,20 We found no associations between
wearing-off symptoms and disease activity markers such as
clinical relapses, new lesions detected by MRI in the past year,
or serum NF-L levels.21
Figure 2 Linear regression analysis demonstrates an association between RO and BMI
Plot of receptor occupancies (A) before and (B) after infusion for indicated cell types as a function of BMI. Solid lines have slopes that are significantly different
from zero (p < 0.05), and dashed lines have slopes that are not significantly different from zero. BMI = body mass index; RO = receptor occupancy.
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As also reported by others,19 we observed large interindividual
variations in natalizumab RO, and not all patients with low
RO had high BMI. A previous study reported that body
weight only partly predicts variability in natalizumab RO and
suggested other factors such as density and turnover of α4β1
integrin that may drive the variability.22
It has been hypothesized that cytokines could induce the
wearing-off symptoms.4,5 We speculate that lower natalizu-
mab RO at the end of the dosing interval could increase the
migratory capacity of cytokine-producing leukocytes into the
CNS resulting in the wearing-off symptoms. We found sig-
nificantly lower RO in the T-cell subtypes CD8+ TEM, CD4
+
TEM, and CD4
+ TEMRA cells before infusion in patients who
regularly had wearing-off symptoms. TEM and TEMRA cells
home to the site of inflammation where they have effector
functions such as secretion of proinflammatory cytokines and
cytotoxicity; in contrast, TCM cells and naive T cells home to
secondary lymphoid organs.23,24
Our results suggest that low RO may be a contributing factor
to the wearing-off phenomenon and that higher BMI may be
an underlying cause. This supports the suggestion that nata-
lizumab dosing should be personalized. Personalization has
been mainly focused on extended interval dosing (EID).19
This has particularly been driven by the risk of progressive
multifocal leukoencephalopathy (PML), a serious complica-
tion of natalizumab therapy in patients previously exposed to
JC virus.25 Retrospective studies of off-label treatment with
EID have shown maintained efficacy26,27 and reduced PML
risk28 compared with standard interval dosing. However,
these studies are limited by possible selection bias due to
nonrandomized design, and the efficacy and safety of EID is
not fully known. As patients who regularly experience
wearing-off symptoms already have lower RO and report
symptoms at the end of dosing intervals, extending dosing
intervals could increase the risk of disease activity. We
therefore do not recommend EID in patients reporting
wearing-off symptoms regularly, as this could lead to an even
lower RO at the end of the interval than observed with
standard dosing.6,19 Further studies should investigate
whether wearing-off symptoms are associated with increased
risk of RRMS disease activity and whether increasing RO by
reduced dosing intervals or weight loss may mitigate the
symptoms.
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